Skip to main content

Table 2 Subgroup analysis of pooled HRs for OS in cancer patients with abnormally expressed MLKL

From: Prognostic and clinicopathological significance of MLKL expression in cancer patients: a meta-analysis

Subgroup analysis No. of studies Pooled HRs Heterogeneity
Fixed I2 p -value
Type of cancer
 Non-digestive system carcinoma 3 0.22[0.11–0.44] 0% 0.866
 Digestive system carcinoma 3 0.30[0.17–0.50] 0% 0.748
Sample size
  < 100 3 0.23[0.11–0.46] 0% 0.806
  ≥ 100 3 0.28[0.17–0.48] 0% 0.704
Follow-up time
  < 100 3 0.28[0.15–0.53] 0% 0.546
  ≥ 100 3 0.25[0.14–0.44] 0% 0.973
NOS score
  < 7 2 0.20[0.08–0.51] 0% 0.627
  ≥ 7 4 0.28[0.18–0.46] 0% 0.873